KR101454013B1 - 자간전증의 진단 및 치료 - Google Patents

자간전증의 진단 및 치료 Download PDF

Info

Publication number
KR101454013B1
KR101454013B1 KR1020097019056A KR20097019056A KR101454013B1 KR 101454013 B1 KR101454013 B1 KR 101454013B1 KR 1020097019056 A KR1020097019056 A KR 1020097019056A KR 20097019056 A KR20097019056 A KR 20097019056A KR 101454013 B1 KR101454013 B1 KR 101454013B1
Authority
KR
South Korea
Prior art keywords
hemoglobin
preeclampsia
level
free
fetal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097019056A
Other languages
English (en)
Korean (ko)
Other versions
KR20100015315A (ko
Inventor
스테판 한슨
보 아케어스트룀
Original Assignee
에이원엠 파마 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이원엠 파마 에이비 filed Critical 에이원엠 파마 에이비
Publication of KR20100015315A publication Critical patent/KR20100015315A/ko
Application granted granted Critical
Publication of KR101454013B1 publication Critical patent/KR101454013B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
KR1020097019056A 2007-02-12 2008-02-12 자간전증의 진단 및 치료 Expired - Fee Related KR101454013B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12
SE0700339-5 2007-02-12
PCT/EP2008/001051 WO2008098734A1 (en) 2007-02-12 2008-02-12 Diagnosis and treatment of preeclampsia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147017284A Division KR101608501B1 (ko) 2007-02-12 2008-02-12 자간전증의 진단 및 치료

Publications (2)

Publication Number Publication Date
KR20100015315A KR20100015315A (ko) 2010-02-12
KR101454013B1 true KR101454013B1 (ko) 2014-11-12

Family

ID=39295873

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147017284A Expired - Fee Related KR101608501B1 (ko) 2007-02-12 2008-02-12 자간전증의 진단 및 치료
KR1020097019056A Expired - Fee Related KR101454013B1 (ko) 2007-02-12 2008-02-12 자간전증의 진단 및 치료

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020147017284A Expired - Fee Related KR101608501B1 (ko) 2007-02-12 2008-02-12 자간전증의 진단 및 치료

Country Status (18)

Country Link
US (3) US8568999B2 (enExample)
EP (3) EP2111555B1 (enExample)
JP (2) JP5604111B2 (enExample)
KR (2) KR101608501B1 (enExample)
AU (1) AU2008214837B2 (enExample)
BR (1) BRPI0808340A2 (enExample)
CA (1) CA2674204C (enExample)
DK (2) DK2614832T3 (enExample)
EA (2) EA031877B1 (enExample)
ES (2) ES2599003T3 (enExample)
HR (2) HRP20130809T1 (enExample)
HU (1) HUE031613T2 (enExample)
MX (2) MX2009008408A (enExample)
NZ (1) NZ578077A (enExample)
PL (2) PL2614832T3 (enExample)
PT (2) PT2614832T (enExample)
WO (1) WO2008098734A1 (enExample)
ZA (1) ZA200905101B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170015619A (ko) 2015-07-29 2017-02-09 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008408A (es) 2007-02-12 2009-11-02 Stefan Hansson Diagnosis y tratamiento de preeclampsia.
HUE030274T2 (en) 2008-07-18 2017-05-29 A1M Pharma Ab The therapeutic use of the root binding and antioxidant alpha-1 microglobulin
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
BR112012024175A2 (pt) * 2010-03-24 2016-07-05 Preelumina Diagnostics Ab hbf e a1m como marcadores de estágio precoce para preeclampsia
KR101858765B1 (ko) * 2010-03-31 2018-05-16 세키스이 메디칼 가부시키가이샤 면역 크로마토그래피를 이용한 측정 방법, 면역 크로마토그래피용 테스트 스트립 및 면역 크로마토그래피용 측정 시약 키트
CA2886489A1 (en) 2011-10-14 2013-04-18 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
CA2881321A1 (en) * 2012-09-05 2014-03-13 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
CA2977458A1 (en) 2015-03-16 2016-09-22 A1M Pharma Ab Biomarkers for preeclampsia
EP3384076A4 (en) 2015-12-04 2019-09-25 Nx Prenatal Inc. USE OF CIRCULATING MICROPARTICLES TO STRATIFY THE RISK ON A SPONTANEOUS SPRING BIRTH
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202516175A (zh) * 2018-03-19 2025-04-16 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
WO2024053586A1 (ja) * 2022-09-05 2024-03-14 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
ATE439588T1 (de) 2001-05-04 2009-08-15 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
ATE360213T1 (de) 2001-09-04 2007-05-15 Iq Corp B V Bestimung und quantifizierung von erythrocytenpopulationen in proben
US20050014275A1 (en) * 2002-03-29 2005-01-20 Fumihisa Kitawaki Blood processing method, blood processing device, method of measuring hemoglobins and device for measuring hemoglobins
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
JP5624256B2 (ja) * 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
EP1689386A1 (en) * 2003-11-26 2006-08-16 Sanofi-Aventis Deutschland GmbH Tubular proteinuria as an indicator for elevated cardiovascular risk
WO2005093413A2 (en) * 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
CA2636353A1 (en) * 2006-01-18 2007-07-26 Georg Wick Test systems for the analysis of polypeptides and cells adhering to silicones
MX2009008408A (es) * 2007-02-12 2009-11-02 Stefan Hansson Diagnosis y tratamiento de preeclampsia.
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
HUE030274T2 (en) 2008-07-18 2017-05-29 A1M Pharma Ab The therapeutic use of the root binding and antioxidant alpha-1 microglobulin
BR112012024175A2 (pt) 2010-03-24 2016-07-05 Preelumina Diagnostics Ab hbf e a1m como marcadores de estágio precoce para preeclampsia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Evaluation of a Capillary Electrophoresis Method for Routine Determination of Hemoglobins A2 and F", Frederic Cotton et al, Clinical Chemistry 45:2, 237-243 (1999) *
"Evaluation of a Capillary Electrophoresis Method for Routine Determination of Hemoglobins A2 and F", Frederic Cotton et al, Clinical Chemistry 45:2, 237-243 (1999)*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170015619A (ko) 2015-07-29 2017-02-09 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법

Also Published As

Publication number Publication date
EA200970758A1 (ru) 2010-02-26
MX2009008408A (es) 2009-11-02
BRPI0808340A2 (pt) 2017-05-30
JP5792772B2 (ja) 2015-10-14
DK2111555T3 (da) 2013-09-02
US20140065170A1 (en) 2014-03-06
CA2674204A1 (en) 2008-08-21
KR101608501B1 (ko) 2016-04-04
EA031877B1 (ru) 2019-03-29
WO2008098734A1 (en) 2008-08-21
AU2008214837A1 (en) 2008-08-21
HRP20161266T1 (hr) 2016-12-16
EP2111555A1 (en) 2009-10-28
US20100105070A1 (en) 2010-04-29
PT2111555E (pt) 2013-09-04
PT2614832T (pt) 2016-10-18
US20180284087A1 (en) 2018-10-04
DK2614832T3 (da) 2016-10-31
JP2010518386A (ja) 2010-05-27
EP2613150A1 (en) 2013-07-10
EP2614832B1 (en) 2016-07-13
NZ578077A (en) 2012-04-27
US10359406B2 (en) 2019-07-23
EP2111555B1 (en) 2013-05-29
EA022609B1 (ru) 2016-02-29
JP5604111B2 (ja) 2014-10-08
CA2674204C (en) 2017-07-11
HUE031613T2 (en) 2017-09-28
JP2014012670A (ja) 2014-01-23
PL2111555T3 (pl) 2013-10-31
ZA200905101B (en) 2012-01-25
US8568999B2 (en) 2013-10-29
EA201500335A1 (ru) 2016-08-31
ES2426069T3 (es) 2013-10-21
MX347788B (es) 2017-05-12
KR20140095572A (ko) 2014-08-01
EP2614832A1 (en) 2013-07-17
AU2008214837B2 (en) 2013-01-10
HRP20130809T1 (xx) 2013-10-11
KR20100015315A (ko) 2010-02-12
ES2599003T3 (es) 2017-01-31
PL2614832T3 (pl) 2017-01-31

Similar Documents

Publication Publication Date Title
KR101454013B1 (ko) 자간전증의 진단 및 치료
Arai et al. Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice
JPWO2005038457A1 (ja) 多量体アディポネクチンの分別測定方法
EP3077815B1 (en) Methods and reagents for the assessment of gestational diabetes
US9835631B2 (en) Combined biomarker measurement of fibrosis
Sun et al. PINK1-mediated mitophagy induction protects against preeclampsia by decreasing ROS and trophoblast pyroptosis
Hsu et al. Proteomic profiling reveals α1-antitrypsin, α1-microglobulin, and clusterin as preeclampsia-related serum proteins in pregnant women
KR20170125975A (ko) 자간전증에 대한 바이오마커
Lu et al. Serum markers of pre‐eclampsia identified on proteomics
Giovanni et al. Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis
ES2543171T3 (es) HbF y A1M como marcadores de fase inicial para preeclampsia
US20230176073A1 (en) Assays and methods for targeted treatment of hydrosalpinx
Zhang et al. Complement component C4A and apolipoprotein AI in plasmas as biomarkers of the severe, early-onset preeclampsia
CN112557664A (zh) Cryab在急性肾损伤检测中的应用及检测试剂盒
EP3594227A1 (en) Immunogenic fragment peptide of en2 protein or antibody composition specifically recognizing same
KR20250062590A (ko) 신장 이식 후 만성거부반응 진단용 조성물
Cheng et al. Proteomic profiling reveals a1-antitrypsin, a1-microglobulin, and clusterin as preeclampsia-related serum proteins in pregnant women
HK40019693A (en) Immunogenic fragment peptide of en2 protein or antibody composition specifically recognizing same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170927

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191017

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191017

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000